|
1）日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会：特発性間質性肺炎—診断と治療の手引き 改訂第2版．東京：南江堂；2011
|
|
|
|
|
2）Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183：788-824
|
|
|
|
|
3）Vancheri C，Failla M，Crimi N，et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010; 35：496-504
|
|
|
|
|
|
4）Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012; 366: 1968-77
|
|
|
|
|
|
5）Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 186: 88-95
|
|
|
|
|
|
6）Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of idiopathic pulmonary fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015; 192: e3-19
|
|
|
|
|
|
7）井上義一. 薬物療法・選択基準 2. ニンテダニブ．In： 吾妻安良太企画，特発性肺線維症とその周辺疾患．大阪：最新医学社；2015. p.164-74
|
|
|
|
|
|
8）Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007; 29: 976-85
|
|
|
|
|
|
9）Hostettler KE, Zhong J, Papakonstantinou E, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res. 2014; 15: 157
|
|
|
|
|
|
10）Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365: 1079-87
|
|
|
|
|
|
11）Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2071-82
|
|
|
|
|
|
12）谷口博之，近藤康博．特発性肺線維症の急性増悪の新しい診断基準について．厚生労働省特定疾患びまん性肺疾患調査研究班，平成15年度研究報告書．2004; 114-9
|
|
|
|
|
|
13）Taniguchi H, Ebina M, Kondoh Y, et al. Pirfeni-done in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 35: 821-9
|
|
|
|
|
|
14）Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across pre-specified subgroups in INPULSISⓇ. Am J Respir Crit Care Med. 2015 Sep 22. [Epub ahead of print]
|
|
|
|
|
|
15）Suissa S, Ernst P. The INPULSIS enigma: exacerbations in idiopathic pulmonary fibrosis. Thorax. 2015; 70: 508-10
|
|
|
|
|